The latest update is out from Organogenesis Holdings ( (ORGO) ).
Organogenesis Holdings Inc. has secured a $130 million private placement deal with Avista Healthcare Partners to bolster its strategic growth, repay debt, and repurchase shares. This investment, through the issuance of Series A Convertible Preferred Stock, offers an 8% annual dividend and conversion rights into common stock at a premium price. The company aims to enhance its financial flexibility and capitalize on growth opportunities in regenerative medicine, while leveraging Avista’s healthcare expertise.
See more insights into ORGO stock on TipRanks’ Stock Analysis page.
